Centessa Pharmaceuticals plc

NASDAQ•CNTA

CEO: Dr. Saurabh Saha M.D., Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2021-05-28

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

連絡先情報

1 Ashley Road, 3rd Floor, Altrincham, WA14 2DT, United Kingdom

N/A

www.centessa.com

時価総額

$3.59B

PER (TTM)

-14.8

19.7

配当利回り

52週高値

$30.58

52週安値

$9.60

52週レンジ

82%

順位73Top 99.9%

0.8

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 0.8 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.41+10.81%

直近4四半期の推移

フリーCF

-$58.55M+173.29%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Genmab License Revenue Recognized Recognized $15.0M upfront revenue from Genmab License Agreement in Q1 2025, boosting nine-month revenue.

R&D Investment Ramps Up R&D expenses increased $33.3M to $117.7M for nine months, focusing on OX2R agonist pipeline advancement.

Cash Position Maintained Cash, equivalents, and investments totaled $349.0M as of September 30, 2025, funding operations into mid-2027.

ORX142 Clinical Advancement Initiated Phase 1 FIH clinical trial for ORX142, the second OX2R agonist candidate, following IND clearance in June 2025.

リスク要因

Net Loss Widens Nine-month net loss increased to $(131.4M) from $(124.4M) due to higher R&D costs and program termination expenses.

Operating Cash Usage Rises Net cash used in operating activities rose to $(138.0M) for nine months, reflecting $28.3M in program termination payments made.

Development Success Uncertain Product candidates face high failure rates; success hinges on demonstrating safety and efficacy in ongoing clinical trials.

Need for Capital Substantial additional capital required to fund ongoing operations and expected increased expenses into mid-2027.

見通し

ORX750 Dose Selection Planned Expect Phase 2a study results to enable dose selection for the registrational program targeted for the first quarter of 2026.

Pipeline Candidates Advancing Planning patient studies for ORX142 in Q1 2026; ORX489 is currently in IND-enabling studies.

Future Financing Anticipated Anticipate needing substantial additional funding to support ongoing development activities and expected commercialization expenses.

Prioritizing OX2R Franchise Strategic decision made to prioritize capital towards the development of the growing OX2R agonist franchise.

同業比較

売上高 (TTM)

APLS

$1.00B

+28.5%

LEGN

$908.96M

+74.7%

RARE

$672.72M

+20.1%

粗利益率 (最新四半期)

SLNO

99.1%

+0.0pp

QURE

92.2%

+33.9pp

RARE

86.0%

-2.4pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CDTX	$5.61B	-18.6	-60.1%	0.4%
IMVT	$5.51B	-10.6	-65.8%	0.0%
CELC	$5.19B	-30.9	-179.0%	67.3%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月23日

EPS:-$0.38

売上高:$708.00K

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし